SCHEMBL29857040

SCHEMBL29857040

CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(Cl)ccc32)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA1 Q13131 13/20 1.00
KDR P35968 12/20 1.00
PRKAA2 P54646 11/20 1.00
PDGFRB P09619 5/20 0.87
FGFR1 P11362 4/20 0.87
EGFR P00533 3/20 0.87
KIT P10721 2/20 0.87
NEK2 P51955 2/20 0.87
MELK Q14680 2/20 0.87
CSF1R P07333 4/20 0.73
FLT3 P36888 3/20 0.73
PLK4 O00444 2/20 0.73
DCLK1 O15075 2/20 0.73
PDPK1 O15530 2/20 0.73
DAPK3 O43293 2/20 0.73
ROCK2 O75116 2/20 0.73
RPS6KA5 O75582 2/20 0.73
RPS6KA4 O75676 2/20 0.73
MAP4K4 O95819 2/20 0.73
CHEK2 O96017 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Su-11652 SCHEMBL29366350 0.93 KDR (1.00) PRKAA1KDRPRKAA2PDGFRBFGFR1
Su-11652 SCHEMBL21067494 0.93 KDR (1.00) PRKAA1KDRPRKAA2PDGFRBFGFR1
Su-11652 SCHEMBL2212420 0.93 KDR (1.00) PRKAA1KDRPRKAA2PDGFRBFGFR1
Su-11652 SCHEMBL2114096 0.93 KDR (1.00) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL29856331 0.91 PRKAA1 (0.84) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL13755235 0.91 PRKAA1 (0.83) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL2116244 0.91 PRKAA1 (0.83) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL31672550 0.91 PRKAA1 (0.83) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL31726860 0.90 KDR (0.87) PRKAA1KDRPRKAA2PDGFRBFGFR1
SCHEMBL29856317 0.90 PRKAA1 (1.00) PRKAA1KDRPRKAA2PDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435059-B2 AMP-activated protein kinase inhibitors and methods of making and using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-10-07 US disclosed
US-20220289707-A1 AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435059-B2 AMP-activated protein kinase inhibitors and methods of making and using the same PRKAA1, PRKAA2, PRKAG1 PRKAA1 1/4885KDR 1564/4885PRKAA2 2/4885
US-20220289707-A1 AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME PRKAA1, PRKAA2, PRKAG1 PRKAA1 1/4885KDR 1564/4885PRKAA2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.